A meta-analysis of the association between CTLA-4 +49 A/G, -318 C/T, and IL-1 polymorphisms and susceptibility to cervical cancer

Neoplasma

Volumn 61, Issue 4, 2014, Pages 481-490

  Lee, Y H ^a   Song, G G ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Cervical cancer; Cytotoxic T lymphocyte antigen 4; Interleukin l; Meta analysis; Polymorphism

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 1;

ALLELE; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; DOMINANT GENE; ETHNICITY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENOTYPE; HOMOZYGOTE; HUMAN; META ANALYSIS; RECESSIVE GENE; UTERINE CERVIX CANCER;

CTLA-4 ANTIGEN; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKIN-1; POLYMORPHISM, GENETIC; PROGNOSIS; UTERINE CERVICAL NEOPLASMS;

EID: 84904399708     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2014_060     Document Type: Article

References (46)

1. PARKIN DM. Global cancer statistics in the year 2000. The lancet oncology 2001; 2: 533-43. http://dx.doi.org/10.1016/S1470-2045(01)00486-7
2. GREENWALD RJ, OOSTERWEGEL MA, VAN DER WOUDE D, KUBAL A, MANDELBROT DA et al. CTLA-4 regulates cell cycle progression during a primary immune response. Eur J Immunol 2002; 32: 366-73. http://dx.doi.org/10.1002/1521-4141(200202)32:2366::AID-IMMU3663.0.CO;2-5
3. LEE YH, HARLEY JB, NATH SK. CTLA-4 polymorphisms and systemic lupus erythematosus (SLE): a meta-analysis. Human genetics 2005; 116: 361-7. http://dx.doi.org/10.1007/s00439-004-1244-1
4. QUEZADA SA, PEGGS KS. Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer. British journal of cancer 2013; 108: 1560-5. http://dx.doi.org/10.1038/bjc.2013.117
5. UEDA H, HOWSON JM, ESPOSITO L, HEWARD J, SNOOK H et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003; 423: 506-11. http://dx.doi.org/10.1038/nature01621
6. WANG XB, ZHAO X, GISCOMBE R, LEFVERT AK. A CTLA-4 gene polymorphism at position -318 in the promoter region affects the expression of protein. Genes and immunity 2002; 3: 233-4. http://dx.doi.org/10.1038/sj.gene.6363869
7. DINARELLO CA. The IL-1 family and inflammatory diseases. Clinical and experimental rheumatology 2002; 20: S1-13.
8. STYLIANOU E, SAKLATVALA J. Interleukin-1. The international journal of biochemistry & cell biology 1998; 30: 1075-9. http://dx.doi.org/10.1016/S1357-2725(98)00081-8
9. CARTER DB, DEIBEL MR, DUNN CJ, TOMICH CS, LABORDE AL et al. Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein. Nature 1990; 344: 633-8. http://dx.doi.org/10.1038/344633a0
10. TARLOW JK, BLAKEMORE AI, LENNARD A, SOLARI R, HUGHES HN et al. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Human genetics 1993; 91: 403-4. http://dx.doi.org/10.1007/BF00217368
11. STEINKASSERER A, KOELBLE K, SIM RB. Length variation within intron 2 of the human IL-1 receptor antagonist protein gene (IL1RN). Nucleic acids research 1991; 19: 5095. http://dx.doi.org/10.1093/nar/19.18.5095
12. GOKHALE P, KERKAR S, TONGAONKAR H, SALVI V, MANIA-PRAMANIK J. CTLA-4 gene polymorphism at position +49 A>G in exon 1: a risk factor for cervical cancer in Indian women. Cancer genetics 2013; 206: 154-61. http://dx.doi.org/10.1016/j.cancergen.2013.04.003
13. LI H, ZHOU YF, GUO HY, SUN T, Zhang WH et al. Association between CTLA-4 gene polymorphism and susceptibility to cervical cancer. Zhonghua zhong liu za zhi [Chinese journal of oncology] 2011; 33: 681-4.
14. JIANG L, LUO RY, ZHANG W, WANG LR, WANG F et al. Single nucleotide polymorphisms of CTLA4 gene and their association with human cervical cancer. Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 2011; 28: 313-7.
15. RAHIMIFAR S, ERFANI N, SARRAF Z, GHADERI A. ctla-4 gene variations may influence cervical cancer susceptibility. Gynecologic oncology 2010; 119: 136-9. http://dx.doi.org/10.1016/j.ygyno.2010.06.006
16. HU L, LIU J, CHEN X, ZHANG Y, LIU L et al. CTLA-4 gene polymorphism +49 A/G contributes to genetic susceptibility to two infection-related cancers-hepatocellular carcinoma and cervical cancer. Human immunology 2010; 71: 888-91. http://dx.doi.org/10.1016/j.humimm.2010.05.023
17. IVANSSON EL, JUKO-PECIREP I, GYLLENSTEN UB. Interaction of immunological genes on chromosome 2q33 and IFNG in susceptibility to cervical cancer. Gynecologic oncology 2010; 116: 544-8. http://dx.doi.org/10.1016/j.ygyno.2009.10.084
18. PAWLAK E, KARABON L, Wlodarska-Polinska I, JEDYNAK A, JONKISZ A et al. Influence of CTLA-4/CD28/ICOS gene polymorphisms on the susceptibility to cervical squamous cell carcinoma and stage of differentiation in the Polish population. Human immunology 2010; 71: 195-200. http://dx.doi.org/10.1016/j.humimm.2009.11.006
19. SOUSA H, SANTOS AM, CATARINO R, PINTO D, MOUTINHO J et al. IL-1RN VNTR polymorphism and genetic susceptibility to cervical cancer in Portugal. Molecular biology reports 2012; 39: 10837-42. http://dx.doi.org/10.1007/s11033-012-1979-z
20. AL-TAHHAN MA, ETEWA RL, EL BEHERY MM. Association between circulating interleukin-1 beta (IL-1beta) levels and IL-1beta C-511T polymorphism with cervical cancer risk in Egyptian women. Molecular and cellular biochemistry 2011; 353: 159-65. http://dx.doi.org/10.1007/s11010-0110782-9
21. QIAN N, CHEN X, HAN S, QIANG F, JIN G et al. Circulating IL-1beta levels, polymorphisms of IL-1B, and risk of cervical cancer in Chinese women. Journal of cancer research and clinical oncology 2010; 136: 709-16. http://dx.doi.org/10.1007/s00432-009-0710-5
22. SINGH H, SACHAN R, GOEL H, MITTAL B. Genetic variants of interleukin-1RN and interleukin-1beta genes and risk of cervical cancer. BJOG: an international journal of obstetrics and gynaecology 2008; 115: 633-8. http://dx.doi.org/10.1111/j.1471-0528.2007.01655.x
23. TAMANDANI DM, SOBTI RC, SHEKARI M, KAUR S, HURIA A. Impact of polymorphism in IL-1RA gene on the risk of cervical cancer. Archives of gynecology and obstetrics 2008; 277: 527-33. http://dx.doi.org/10.1007/s00404-0070504-4
24. KANG S, KIM JW, PARK NH, SONG YS, PARK SY ET AL. Interleukin-1 beta-511 polymorphism and risk of cervical cancer. Journal of Korean medical science 2007; 22: 110-3. http://dx.doi.org/10.3346/jkms.2007.22.1.110
25. MUSTEA A, SEHOULI J, KONSGEN D, STENGEL D, SOFRONI D et al. Interleukin 1 receptor antagonist (IL-1RA) polymorphism in women with cervical cancer. Anticancer research 2003; 23: 1099-102.
26. LEE YH, WITTE T, MOMOT T, SCHMIDT RE, KAUFMAN KM, HARLEY JB et al. The mannose-binding lectin gene polymorphisms and systemic lupus erythematosus: two casecontrol studies and a meta-analysis. Arthritis and rheumatism 2005; 52: 3966-74. http://dx.doi.org/10.1002/art.21484
27. NATH SK, HARLEY JB, LEE YH. Polymorphisms of complement receptor 1 and interleukin-10 genes and systemic lupus erythematosus: a meta-analysis. Human genetics 2005; 118: 225-34. http://dx.doi.org/10.1007/s00439-005-0044-6
28. LEE YH, HARLEY JB, NATH SK. Meta-analysis of TNF-alpha promoter -308 A/G polymorphism and SLE susceptibility. European journal of human genetics: EJHG 2006; 14: 364-71. http://dx.doi.org/10.1038/sj.ejhg.5201566
29. EGGER M, DAVEY SMITH G, SCHNEIDER M, MINDER C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34. http://dx.doi.org/10.1136/bmj.315.7109.629
30. HIGGINS JP, THOMPSON SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-58. http://dx.doi.org/10.1002/sim.1186
31. DERSIMONIAN R, LAIRD N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88. http://dx.doi.org/10.1016/0197-2456(86)90046-2
32. GRIMM C, WATROWSKI R, BAUMUHLNER K, NATTER C, TONG D et al. Genetic variations of interleukin-1 and -6 genes and risk of cervical intraepithelial neoplasia. Gynecologic oncology 2011; 121: 537-41. http://dx.doi.org/10.1016/j.ygyno.2011.02.019
33. SOBTI RC, KORDI TAMANDANI DM, SHEKARI M, KAUR P, MALEKZADEH K et al. Interleukin 1 beta gene polymorphism and risk of cervical cancer. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 2008; 101: 47-52. http://dx.doi.org/10.1016/j.ijgo.2007.10.014
34. GRIBBEN JG, FREEMAN GJ, BOUSSIOTIS VA, RENNERT P, JELLIS CL et al. CTLA4 mediates antigen-specific apoptosis of human T cells. Proc Natl Acad Sci U S A 1995; 92: 811-5. http://dx.doi.org/10.1073/pnas.92.3.811
35. HAN S, LI Y, MAO Y, XIE Y. Meta-analysis of the association of CTLA-4 exon-1 +49A/G polymorphism with rheumatoid arthritis. Hum Genet 2005; 118: 123-32. http://dx.doi.org/10.1007/s00439-005-0033-9
36. ZHENG J, YU X, JIANG L, XIAO M, BAI B et al. Association between the Cytotoxic T-lymphocyte antigen 4 +49G > A polymorphism and cancer risk: a meta-analysis. BMC cancer 2010; 10: 522. http://dx.doi.org/10.1186/1471-240710-522
37. HE B, ZHANG Y, PAN Y, XU Y, GU L et al. Interleukin 1 beta (IL1B) promoter polymorphism and cancer risk: evidence from 47 published studies. Mutagenesis 2011; 26: 637-42. http://dx.doi.org/10.1093/mutage/ger025
38. STEELE JC, MANN CH, ROOKES S, ROLLASON T, MURPHY D et al. T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia. British journal of cancer 2005; 93: 248-59. http://dx.doi.org/10.1038/sj.bjc.6602679
39. STANCZUK GA, SIBANDA EN, PERREY C, CHIRARA M, PRAVICA V et al. Cancer of the uterine cervix may be significantly associated with a gene polymorphism coding for increased IL-10 production. International journal of cancer Journal international du cancer 2001; 94: 792-4. http://dx.doi.org/10.1002/ijc.1543
40. SIMONART T, VAN VOOREN JP. Interleukin-1 beta increases the BCL-2/BAX ratio in Kaposi's sarcoma cells. Cytokine 2002; 19: 259-66. http://dx.doi.org/10.1006/cyto.2002.1964
41. ASSCHERT JG, VELLENGA E, HOLLEMA H, VAN DER ZEE AG, DE VRIES EG. Expression of macrophage colony-stimulating factor (M-CSF), interleukin-6, (IL-6), interleukin-1 beta (IL-1 beta), interleukin-11 (IL-11) and tumour necrosis factor-alpha (TNF-alpha) in p53-characterised human ovarian carcinomas. European journal of cancer 1997; 33: 2246-51. http://dx.doi.org/10.1016/S0959-8049(97)00240-2
42. HALL SK, PERREGAUX DG, GABEL CA, WOODWORTH T, DURHAM LK et al. Correlation of polymorphic variation in the promoter region of the interleukin-1 beta gene with secretion of interleukin-1 beta protein. Arthritis and rheumatism 2004; 50: 1976-83. http://dx.doi.org/10.1002/art.20310
43. DRIPPS DJ, VERDERBER E, NG RK, THOMPSON RC, EISENBERG SP. Interleukin-1 receptor antagonist binds to the type II interleukin-1 receptor on B cells and neutrophils. The Journal of biological chemistry 1991; 266: 20311-5.
44. VAMVAKOPOULOS J, GREEN C, METCALFE S. Genetic control of IL-1beta bioactivity through differential regulation of the IL-1 receptor antagonist. European journal of immunology 2002; 32: 2988-96. http://dx.doi.org/10.1002/1521-4141(2002010)32:102988::AIDIMMU29883.0.CO;2-9
45. HURME M, SANTTILA S. IL-1 receptor antagonist (IL1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1beta genes. European journal of immunology 1998; 28: 2598-602. http://dx.doi.org/10.1002/(SICI)15214141(199808)28:082598::AID-IMMU25983.0.CO;2-K
46. WITKIN SS, GERBER S, LEDGER WJ. Influence of interleukin-1 receptor antagonist gene polymorphism on disease. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2002; 34: 204-9. http://dx.doi.org/10.1086/338261